Volume : 11, Issue : 10, October – 2024
Title:
AN OVERVIEW OF GLOMERULONEPHRITIS
Authors :
Rasha Khaled Sendy, Alhassan Mubarak Ali Alyami, Ghazy Radhy Al Hamad, Nahla Shaker Saati, Mohammed Abdulrahman Aljohani, Rawan Mohammed Hakami, Fairooz Othman Fadlelseed, Abdullah Matar Almutairi, Abdulaziz Saud Almordhi, Haya Fahad Alsuwailem, Huda Baqer Aljubarah, Ali Ahmed Alkhulif, Anwar Fahad Alkhamis, Hussain Ahmed Alaesh
Abstract :
Background: Glomerulonephritis (GN) encompasses various kidney conditions distinguished by the inflammation of glomeruli. Overlooking these health concerns adequately might cause serious health implications and has the chance to evolve into chronic kidney disease (CKD) or end-stage renal disease (ESRD). GN can be categorized by histopathological patterns, immunopathogenesis, or clinical presentation, offering insights into possible treatments.
Objective: an overview of the types, pathogenesis, diagnosis, and management of (GN).
Methods: a comprehensive review of (GN) and therapy. The PUBMED and Google Scholar search engines were the main databases used for the search process, with articles collected from 2001 to 2024.
Conclusion: (GN) is a complex, immune-mediated kidney disease with diverse clinical forms that demand precise diagnostic and therapeutic approaches. Advanced techniques such as histopathology and immunofluorescence are indispensable for accurate classification, enabling healthcare providers to implement targeted, patient-centered treatment strategies. Effective management, especially in conditions like IgA nephropathy and focal segmental glomerulosclerosis, integrates ACE inhibitors, ARBs, corticosteroids, and, in complex cases, immunosuppressive therapies to reduce inflammation and preserve kidney function. Patients with GN face significant risks, including the progression to chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as cardiovascular and electrolyte complications. Prompt intervention and tailored care, guided by KDIGO Clinical Practice Guidelines, are vital for improving patient outcomes, particularly in low- and middle-income countries where resources may be limited. By combining clinical, laboratory, and imaging assessments, and by continuing research into GN’s immunopathology, healthcare providers can enhance long-term care strategies and effectively address the unique challenges posed by this multifaceted disease.
Keywords: Glomerulonephritis, Classification, Clinical Presentation, Management, Complications.
Cite This Article:
Please cite this article in press Rasha Khaled Sendy et al., An Overview Of Glomerulonephritis..,Indo Am. J. P. Sci, 2024; 11 (10).
Number of Downloads : 10
References:
1. Ekrikpo U, Obiagwu P, Chika-Onu U, Yadla M, Karam S, Tannor EK, et al. Epidemiology and Outcomes of Glomerular Diseases in Low- and Middle-Income Countries. Seminars in Nephrology. 2022;42(5).
2. Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, et al. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). 2020;24:526-40.
3. Cole BR, Valdes AJ. Pathology and Pathophysiology of Proteinuric Glomerular Disease. In: Klahr S, editor. The Kidney and Body Fluids in Health and Disease. Boston, MA: Springer US; 1983. p. 399-438.
4. Wilson CB, Dixon FJ. Immunopathologic mechanisms of renal disease. Ricerca in clinica e in laboratorio. 1975;5(1):17-38.
5. Kronbichler A, Lee KH, Denicolo S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-Associated Vasculitis. 2020;21(19):7319.
6. Falk RJ, Jennette JC. A Nephrological View of the Classification of Vasculitis. In: Gross WL, editor. ANCA-Associated Vasculitides: Immunological and Clinical Aspects. Boston, MA: Springer US; 1993. p. 197-208.
7. Risdon RA, Turner DR. Diffuse Endocapillary and Mesangial Proliferative (GN). Atlas of Renal Pathology. Dordrecht: Springer Netherlands; 1980. p. 43-6.
8. Ellison B, Cader R, Willcocks L. Advances in primary (GN). 2024;85(7):1-11.
9. Kim MJ, Kim SW. Differential Diagnosis of Secondary (GN). Korean J Med. 2013;84(1):19-27.
10. Elzouki AY. Poststreptococcal Acute (GN). In: Elzouki AY, Harfi HA, Nazer HM, Stapleton FB, Oh W, Whitley RJ, editors. Textbook of Clinical Pediatrics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 2743-8.
11. Скворцов ВВ, Тумаренко АВ, Малякин ГИ, Голиева ЭАJСвоп. Современные подходы к фармакотерапии хронического гломерулонефрита. 2020(8):36-45.
12. Sharma R, Sharma K, Bala M, editors. Analysis of Histopathological Images: An Overview. 2022 International Conference on Computing, Communication, Security and Intelligent Systems (IC3SIS); 2022 23-25 June 2022.
13. Bhuiyan ANMSI, Zahangir A, Khondaker Zahirul H, Md Mostafa Z, Md Z. A Clinical Profile and Immediate Outcome of Acute (GN) (AGN) in Hospitalized Children. American Journal of Pediatrics. 2020;6(4):448-54.
14. Sethi S, De Vriese AS, Fervenza FC. Acute (GN). The Lancet. 2022;399(10335):1646-63.
15. Said S, Valeri A, Stokes MB, Masani N, D’Agati V, Markowitz G. Membranous (GN) with ANCA-Associated Necrotizing and Crescentic (GN). Clinical Journal of the American Society of Nephrology : CJASN. 2009;4:299-308.
16. Ceaser R. Histopathological Study of Glomerular Disaese (in Patients with Significant Proteinuria): A Study of 50 Cases: Stanley Medical College, Chennai; 2007.
17. Buchanan CE. Development of MRI techniques for the assessment of chronic kidney disease: University of Nottingham; 2016.
18. Zarbock A, John S, Jörres A, Kindgen-Milles D. Neue KDIGO-Leitlinien zur akuten Nierenschädigung. Der Anaesthesist. 2014;63(7):578-88.
19. Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini MJGIdNOUDSIdN. Management of IgA nephropathy. 2011;28(6):622-32.
20. McIntyre C, Fluck R, Lambie SJCn. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. 2001;56(3):193-8.
21. Grcevska L, Polenakovic MJP. Mycophenolate mofetil in the treatment of glomerular diseases. 2007;28(1):57-68.
22. Alberici F, Tedesco M, Popov T, Balcells-Oliver M, Mescia FJFiI. Treatment goals in ANCA-associated vasculitis: defining success in a new era. 2024;15:1409129.
23. Busch M, Gerth J, Ott U, Schip A, Haufe CC, Gröne H-J, et al. Behandlung der idiopathischen membranösen (GN). Medizinische Klinik. 2008;103(7):519-24.
24. Snively CS, Gutierrez CJAfp. Chronic kidney disease: prevention and treatment of common complications. 2004;70(10):1921-8.
25. Marik PE. Acute Kidney Injury. Evidence-Based Critical Care. Cham: Springer International Publishing; 2015. p. 653-68.
26. Niaudet P. Congenital Nephrotic Syndrome. In: Elzouki AY, Harfi HA, Nazer HM, Stapleton FB, Oh W, Whitley RJ, editors. Textbook of Clinical Pediatrics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 2793-8.
27. Chemello C, Aguilera M, Garre MC, Hernández MAC. Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation. In: Barh D, Dhawan D, Ganguly NK, editors. Omics for Personalized Medicine. New Delhi: Springer India; 2013. p. 801-17.
28. Hauser GJ, Kulick AF. Electrolyte Disorders in the PICU. In: Wheeler DS, Wong HR, Shanley TP, editors. Pediatric Critical Care Medicine: Volume 3: Gastroenterological, Endocrine, Renal, Hematologic, Oncologic and Immune Systems. London: Springer London; 2014. p. 147-71.
29. Shilov E, Tareeva I, Ivanov A, Troepol’skaia O, Krasnova T, Varshavskiĭ V, et al. The course and prognosis of mesangioproliferative (GN). 2002;74(6):11-8.
30. Polenakovic MH, Grcevska L, Dzikova SJNDT. The incidence of biopsy-proven primary (GN) in the Republic of Macedonia—long-term follow-up. 2003;18(suppl_5):v26-v7.